Changing cyclosporin A formulation: An analysis in paediatric cardiac transplant recipients

Pediatric Transplantation

Volumn 3, Issue 3, 1999, Pages 215-218

  Gennery, A R ^a   O'Sullivan, J J ^a   Hasan, A ^a   Hamilton, J R L ^a   Dark, J H ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Cardiac transplantation; Cyclosporin; Renal function

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; RETROSPECTIVE STUDY;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DATA INTERPRETATION, STATISTICAL; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; RETROSPECTIVE STUDIES;

EID: 0032784961     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00033.x     Document Type: Article

References (13)

1. PTACHCINSKI RJ, VENKATARAMANAN R, BURCKART GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986: 11: 107-132.
2. HONCHARIK N, YATSCOFF RW, JEFFERY JR, RUSH DN. The effect of meal composition on cyclosporine absorption. Transplantation 1991: 52: 1087-1089.
3. TRULL A, HUE K, TAN K, et al. Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients. Clin Chem 1990: 36: 1474-1478.
4. DREWE J, BEGLINGER C, KISSEL T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992: 33: 39-43.
5. MEULLER EA, KOVARICK JM, VAN BREE JB, GREVEL J, LUCKER PW, KUTZ K. Influence of a fat rich meal on the pharmacokinetics of a new oral formulation of cyclosporin in a crossover comparison with the market formulation. Pharm Res 1994: 77: 151-155.
6. LEVY G, ALTRAIF I, REZEIG M, et al. Cyclosporin neoral in liver transplant recipients. Transplant Proc 1994: 26: 3184-3187.
7. ALTRAIF I, LEVY G, GRANT D. Pharmacokinetic studies of Sandimmune Neoral in liver transplant recipients. Hepatol 1993: 18: 75A(Abstract).
8. TAN KKC, TRULL AK, UTTRIDGE JA, WALLWORK J. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995: 48: 285-289.
9. BENNETT WM, DEMATTOS A, NORMAN JD, MEYER MM, OLYAEI A. Which cyclosporin formulation? Lancet 1996: 448: 205(Letter).
10. BOKENKAMP A, OFFNER G, HOYER PF, WONIGEIT K, BRODEHL J. Excessive cyclosporin trough level variation with classic cyclosporin can be reduced with the new microemulsion formulation of cyclosporin. Transplant Proc 1996: 28: 2273-2275.
11. COUNAHAN R, CHANTLER C, GHAZALI S, KIRKWOOD B, ROSE F, BARRETT TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976: 51: 875-878.
12. TAN KKC, HUE KL, STRICKLAND S, et al. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit 1990: 12: 520-524.
13. MEULLER EA, KOVARICK JM, VAN BREE JB, TETZLOF W, GREVEL J, KUTZ K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994: 77: 301-304.